Zoetis Inc. (NYSE:ZTS)

Total revenue exhibited a consistent upward trajectory over the five-year period from 2019 to 2023, increasing from US$ 6,260 million to US$ 8,544 million. This growth was characterized by a significant shift in the revenue mix, where rapid expansion in specific pharmaceutical categories offset declines in other therapeutic areas.

Primary Growth Drivers

The most substantial growth was observed in Parasiticides and Dermatology. Parasiticides revenue more than doubled, rising from US$ 966 million in 2019 to US$ 1,947 million in 2023. Similarly, Dermatology grew from US$ 770 million to US$ 1,427 million, establishing both segments as critical contributors to the overall revenue increase.

Steady Revenue Contributors

Vaccines and Other pharmaceuticals demonstrated stable, incremental growth. Vaccines increased from US$ 1,483 million in 2019 to US$ 1,771 million in 2023. Other pharmaceuticals showed a strong upward trend, growing from US$ 780 million to US$ 1,280 million over the same period.

Declining Revenue Streams

A sustained downward trend was evident in Anti-infectives and Medicated feed additives. Anti-infectives revenue decreased from US$ 1,254 million in 2019 to US$ 1,057 million in 2023. Medicated feed additives followed a similar pattern of decline, falling from US$ 470 million to US$ 354 million.

Ancillary and Marginal Segments

Animal health diagnostics showed moderate growth, increasing from US$ 268 million to US$ 376 million. Other non-pharmaceuticals experienced slight growth, rising from US$ 184 million to US$ 254 million. Contract manufacturing and human health remained relatively stagnant, ending the period at US$ 78 million compared to US$ 85 million in 2019.